Holen Sie sich die Stockscreener-App
0.8418
0.95%
-0.0081
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DRRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.8499
Offen:
$0.86
24-Stunden-Volumen:
47,392
Relative Volume:
0.46
Marktkapitalisierung:
$26.13M
Einnahmen:
$8.59M
Nettoeinkommen (Verlust:
$-17.07M
KGV:
-1.38
EPS:
-0.61
Netto-Cashflow:
$-21.90M
1W Leistung:
-0.96%
1M Leistung:
-11.39%
6M Leistung:
-47.06%
1J Leistung:
+14.98%
1-Tages-Spanne:
$0.8203
$0.8645
1-Wochen-Bereich:
$0.7906
$0.8645
52-Wochen-Spanne:
$0.6802
$1.88
Durect Corp Stock (DRRX) Company Profile
Firmenname
Durect Corp
Sektor
Telefon
(408) 777-1417
Adresse
10240 BUBB ROAD, CUPERTINO, CA
Vergleichen Sie DRRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
0.8418 | 26.13M | 8.59M | -17.07M | -21.90M | -0.61 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-10-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-12 | Eingeleitet | ROTH Capital | Buy |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-31 | Eingeleitet | B. Riley FBR | Buy |
| 2019-11-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-06 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2017-10-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2017-10-20 | Bestätigt | Laidlaw | Buy |
| 2017-10-20 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2017-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-04-25 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-05-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-05-01 | Bestätigt | Stifel | Buy |
| 2013-03-25 | Eingeleitet | Stifel | Buy |
| 2012-11-01 | Herabstufung | C.K. Cooper | Buy → Hold |
| 2012-08-17 | Eingeleitet | C.K. Cooper | Buy |
| 2009-06-23 | Eingeleitet | Caris & Company | Buy |
| 2009-03-26 | Eingeleitet | Wedbush Morgan | Hold |
Alle ansehen
Durect Corp Aktie (DRRX) Neueste Nachrichten
Durect (DRRX) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Geode Capital Management LLC Has $429,000 Holdings in DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT faces Nasdaq delisting over share price - Investing.com
Reviewing Acerus Pharmaceuticals (OTCMKTS:TRLPF) and DURECT (NASDAQ:DRRX) - Defense World
Durect (DRRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
DURECT Corp expected to post a loss of 17 cents a shareEarnings Preview - XM
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
DURECT Corp sells ALZET product line to Lafayette - TradingPedia
Durect announces sale of Alzet line of osmotic pumps to LIC for $17.5M - TipRanks
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million - PR Newswire
DURECT Sells ALZET Product Line for $17.5M, Extends Cash Runway to 2025 - StockTitan
DURECT Corporation (NASDAQ:DRRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corporation reports Q3 2024 financials - Investing.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... - Yahoo Finance
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... By GuruFocus - Investing.com Canada
Durect: Q3 Earnings Snapshot - Houston Chronicle
Durect Corp Q3 2024 Earnings: GAAP EPS of -$0.14 Misses Estimates, Revenue at $1.9 Million Below Expectations - GuruFocus.com
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Durect reports Q3 EPS (14c), consensus (17c) - TipRanks
DURECT Q3: $4.3M Loss, Plans Phase 3 Trial Amid Funding Needs & License Agreement End | DRRX Stock News - StockTitan
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - StockTitan
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights
DRRXDurect Corp Latest Stock News & Market Updates - StockTitan
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 - StockTitan
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ... - Yahoo Finance
Durect Corp Annual Meeting Decisions and Shareholder Votes - TipRanks
H.C. Wainwright maintains Neutral rating on Durect shares post FDA meeting - Investing.com
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - PR Newswire
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - PR Newswire
Durect Corp (NQ: DRRX - Financial Content
Durect (FRA:DC8A) Total Inventories : €2.30 Mil (As of Jun. 2024) - GuruFocus.com
DURECT Co. (NASDAQ:DRRX) Expected to Post Q3 2024 Earnings of ($0.14) Per Share - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corp reports steady Q2 financials, plans Phase III trial - Investing.com India
Durect: Q2 Earnings Snapshot - Houston Chronicle
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - PR Newswire
DURECT (DRRX) Set to Announce Quarterly Earnings on Tuesday - Defense World
DURECT Co. (NASDAQ:DRRX) Receives $27.50 Average Target Price from Brokerages - American Banking and Market News
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update - StockTitan
ProAssurance Co. (NYSE:PRA) Shares Bought by CANADA LIFE ASSURANCE Co - Defense World
DURECT (DRRX) Stock Price, News & Analysis - MarketBeat
Altair Engineering (NASDAQ:ALTR) Stock Rating Lowered by The Goldman Sachs Group - Defense World
DURECT (NASDAQ:DRRX) Stock Price Passes Above Two Hundred Day Moving Average of $1.13 - MarketBeat
Durect - The Pharma Letter
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - PR Newswire
DURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call Transcript - Insider Monkey
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update - PR Newswire
Finanzdaten der Durect Corp-Aktie (DRRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):